Updates in Medicine REDEFINE 2: CagriSema in T2D + Obesity Original article link in bio Phase 3a RCT in 1206 adults with T2D (BMI 27, HbA1c 710%) Instagram What is the pipeline for future medications for obesity? International Journal of Obesity Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE 1 Trial? Seeking Alpha CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet